Vanguard Global Advisers
AZN icon

Vanguard Global Advisers’s AstraZeneca AZN Stock Holding History

Vanguard Global Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84M Buy
450,083
+26,111
+6% +$4.91M 0.04% 310
2026
Q1 		$82.9M Buy
+423,972
New +$81.7M 0.04% 302

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $18.4B AUM 23.98% 1-Year Est. Return

Vanguard Global Advisers's AZN Position: Q2 2026 in Review

Vanguard Global Advisers increased its AstraZeneca (AZN) stake by 6.2% in Q2 2026, buying an estimated $4.91M and bringing the position to 450,083 shares worth $84M. The position accounts for 0.04% of the portfolio, ranked #310.

Vanguard Global Advisers first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,425 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Vanguard Global Advisers held 450,083 shares of AstraZeneca worth $84M as of Q2 2026.
  • Vanguard Global Advisers bought 26,111 AstraZeneca shares in Q2 2026, an estimated $4.91M.
  • AstraZeneca made up 0.04% of Vanguard Global Advisers's portfolio in Q2 2026, its #310 holding.
  • Vanguard Global Advisers first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
  • 1,425 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.